These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1357542)
1. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Lahti RA; Figur LM; Piercey MF; Ruppel PL; Evans DL Mol Pharmacol; 1992 Sep; 42(3):432-8. PubMed ID: 1357542 [TBL] [Abstract][Full Text] [Related]
2. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976 [TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes. Odagaki Y; Toyoshima R Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659 [TBL] [Abstract][Full Text] [Related]
4. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. Cumming P; Wong DF; Gillings N; Hilton J; Scheffel U; Gjedde A J Cereb Blood Flow Metab; 2002 May; 22(5):596-604. PubMed ID: 11973432 [TBL] [Abstract][Full Text] [Related]
5. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride. Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171 [TBL] [Abstract][Full Text] [Related]
6. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553 [TBL] [Abstract][Full Text] [Related]
7. Expression and pharmacological characterization of the human D3 dopamine receptor. Freedman SB; Patel S; Marwood R; Emms F; Seabrook GR; Knowles MR; McAllister G J Pharmacol Exp Ther; 1994 Jan; 268(1):417-26. PubMed ID: 8301582 [TBL] [Abstract][Full Text] [Related]
8. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087 [TBL] [Abstract][Full Text] [Related]
13. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Olianas MC; Maullu C; Onali P Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494 [TBL] [Abstract][Full Text] [Related]
14. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. Claustre Y; Fage D; Zivkovic B; Scatton B J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197 [TBL] [Abstract][Full Text] [Related]
15. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773 [TBL] [Abstract][Full Text] [Related]
16. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. LaHoste GJ; Marshall JF Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762 [TBL] [Abstract][Full Text] [Related]
17. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753 [TBL] [Abstract][Full Text] [Related]
18. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370 [TBL] [Abstract][Full Text] [Related]
19. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. Robertson GS; Tham CS; Wilson C; Jakubovic A; Fibiger HC J Pharmacol Exp Ther; 1993 Mar; 264(3):1344-51. PubMed ID: 8095550 [TBL] [Abstract][Full Text] [Related]
20. Differential pharmacological profile of striatal and cerebellar dopamine receptors labeled by [3H]quinpirole: identification of a discrete population of putative D3 receptors. Levant B; DeSouza EB Synapse; 1993 May; 14(1):90-5. PubMed ID: 8099762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]